Coinciding with the August announcement of Sue Fletcher to the position of CSO of PYC is the August publication of an article Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson's disease in the precision medicine era; Fletcher is listed as a contributing author.
Its of interest that the CSO highlighted the expansion of PYCs approach to the central nervous system. All along the utility and promise of PMOs has been held back by the lack of an efficient delivery system. Its a brave new world with the potential for life changing impact.
Coinciding with the August announcement of Sue Fletcher to the...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.25 |
Change
-0.030(2.35%) |
Mkt cap ! $729.0M | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.27 | $1.25 | $63.95K | 51.08K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 18084 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.26 | 5800 | 2 |
View Market Depth
| Last trade - 11.24am 31/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |